Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Table 3 Novel epigenetic targeted agents and combinations in R/R PTCL

Drug name	Molecular target	Study design, n	ORR	CR	Survival outcomes^#	Reference
Azacytidine	DNMT	Phase III, 86	33%	12%	PFS 5.6 months OS 18.4 months	[98]
Guadecitabine	DNMT	Phase II, 20	40%	10%	PFS 2.9 months OS 10.4 months	[99]
Romidepsin plus ICE	HDAC	Phase I, 18	93%	80%	PFS 10 months OS 15 months	[105]
Romidepsin plus Pralatrexate	HDAC/DHFR	Phase I, 14	71%	29%	PFS 4.4 months OS 12.4 months	[106]
Romidepsin plus Azacytidine	HDAC/DNMT	Phase I, 11	73%	55%	PFS not reached	[110]
Romidepsin plus Azacytidine	HDAC/DNMT	Phase II, 14	54%	38%	PFS 8.0 months OS 20.6 months	[111]
Tucidinostat plus Azacytidine	HDAC/DNMT	Phase I, 19	56%	-	PFS 6.5 months OS 17.5 months	[114]
Tucidinostat plus Parsaclisib	HDAC/ PI3Kδ	Phase Ib/II, 11	67%	56%	-	[115]
Valemetostat	EZH2	Phase I, 57	55%	31%	PFS 7.7 months	[116]
Valemetostat	EZH2	Phase II, 119	52%	27%	PFS 5.5 months OS 17.0 months	[117]
SHR2554	EZH2	Phase I, 28	61%	11%	PFS 11.1 months 12-month OS 92%	[118]
HH2853	EZH2	Phase Ib, 28	61%	21%	3-month PFS 74% 6-month OS 92%	[119]

ISSN: 1756-8722